IOVA - Iovance Biotherapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

IOVA is currently covered by 13 analysts with an average price target of $11.93. This is a potential upside of $9.29 (351.89%) from yesterday's end of day stock price of $2.64.

Iovance Biotherapeutics's activity chart (see below) currently has 218 price targets and 201 ratings on display. The stock rating distribution of IOVA is 91.67% BUY and 8.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 44.07% with an average time for these price targets to be met of 178.25 days.

Highest price target for IOVA is $25, Lowest price target is $1, average price target is $15.11.

Most recent stock forecast was given by GEULAH LIVSHITS from CHARDAN CAPITAL on 23-Jul-2025. First documented stock forecast 03-Aug-2017.

Currently out of the existing stock ratings of IOVA, 55 are a BUY (91.67%), 5 are a HOLD (8.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$25

$22.36 (846.97%)

$25

17 days ago
(23-Jul-2025)

3/17 (17.65%)

$21.03 (529.72%)

137

Hold

$1

$-1.64 (-62.12%)

$8

25 days ago
(15-Jul-2025)

1/7 (14.29%)

$-0.94 (-48.45%)

92

Buy

$4

$1.36 (51.52%)

$5

2 months 28 days ago
(12-May-2025)

3/9 (33.33%)

$2.07 (107.25%)

105

Buy

$15

2 months 28 days ago
(12-May-2025)

4/11 (36.36%)

$10.76 (253.77%)

215

Buy

$10

$7.36 (278.79%)

$30

2 months 28 days ago
(12-May-2025)

0/7 (0%)

$8.07 (418.13%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is IOVA (Iovance Biotherapeutics) average time for price targets to be met?

On average it took 178.25 days on average for the stock forecasts to be realized with a an average price target met ratio 44.07

Which analyst has the current highest performing score on IOVA (Iovance Biotherapeutics) with a proven track record?

GEULAH LIVSHITS

Which analyst has the most public recommendations on IOVA (Iovance Biotherapeutics)?

Geulah Livshits works at CHARDAN CAPITAL and has 11 price targets and 12 ratings on IOVA

Which analyst is the currently most bullish on IOVA (Iovance Biotherapeutics)?

Biren Amin with highest potential upside - $40.36

Which analyst is the currently most reserved on IOVA (Iovance Biotherapeutics)?

Andrea Tan with lowest potential downside - -$1.64

Iovance Biotherapeutics in the News

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -13.79%. A quarter ago, it...

Iovance Biotherapeutics Reports Financial ResultsĀ and Corporate Updates for Second Quarter and First Half 2025

$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with AmtagviĀ® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?